|
TMTC4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.76149999826004E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.02349999773355E-08 |
| Normal-vs-Stage2 |
6.35989999997477E-07 |
| Normal-vs-Stage3 |
5.69370000036429E-07 |
| Normal-vs-Stage4 |
5.816400E-04 |
| Stage1-vs-Stage2 |
2.927200E-01 |
| Stage1-vs-Stage3 |
6.384200E-01 |
| Stage1-vs-Stage4 |
7.390600E-01 |
| Stage2-vs-Stage3 |
4.881600E-01 |
| Stage2-vs-Stage4 |
6.549600E-01 |
| Stage3-vs-Stage4 |
9.588800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.27449999945506E-08 |
| Normal-vs-AfricanAmerican |
9.276400E-03 |
| Normal-vs-Asian |
1.361930E-04 |
| Caucasian-vs-AfricanAmerican |
3.722800E-01 |
| Caucasian-vs-Asian |
9.160800E-01 |
| AfricanAmerican-vs-Asian |
4.631400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.94359999988936E-07 |
| Normal-vs-Female |
1.18809999616332E-08 |
| Male-vs-Female |
9.434200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.65430000043499E-07 |
| Normal-vs-Age(41-60Yrs) |
3.94789999580425E-08 |
| Normal-vs-Age(61-80Yrs) |
1.26600000038835E-07 |
| Normal-vs-Age(81-100Yrs) |
5.169700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.018000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.099400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.719200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.717600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.396800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.091000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.800200E-01 |
| Classical-VS-Follicular |
6.035200E-03 |
| Classical-VS-Other |
6.869800E-01 |
| Classical-VS-Normal |
2.98470000004158E-06 |
| Tall-VS-Follicular |
1.655350E-01 |
| Tall-VS-Other |
8.132000E-01 |
| Tall-VS-Normal |
1.617340E-04 |
| Follicular-VS-Other |
5.998400E-01 |
| Follicular-VS-Normal |
6.21179996329602E-09 |
| Other-VS-Normal |
1.961840E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.53839949060364E-10 |
| Normal-vs-N1 |
2.179500E-03 |
| N0-vs-N1 |
2.263000E-01 |
|
|
